Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
They deliver clinically proven results, often with significant weight loss outcomes in medical trials
Retatrutide activates three hormone receptors: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors
Based on the typical UK regulatory pathway, the most realistic timeline is: Late 2026 / early 2027: Eli Lilly expected to submit regulatory filings to the FDA and MHRA following completion of the remaining TRIUMPH Phase 3 readouts Late 2027 to mid-2028: Possible MHRA marketing authorisation, allowing private UK prescribing 2028 to 2029 onwards: Possible NHS availability following a NICE technology appraisal and NHS commissioning decisions Timelines may differ across the four UK nations, as Scotland, Wales, and Northern Ireland assess medicines separately through the Scottish Medicines Consortium (SMC), All Wales Medicines Strategy Group (AWMSG), and the Department of Health Northern Ireland respectively
Comprehensive assessment first before prescribing anything, we assess your metabolic health, hormonal patterns, inflammatory markers, and lifestyle factors to understand WHY your body is holding onto weight
US$ 28.11
US$ 29.92
US$ 22.27
US$ 23.05
US$ 22.90
US$ 26.46
US$ 25.24
